Macrophage Pharma names Søren Bregenholt as CEO

3 September 2019

UK-based immuno-oncology company Macrophage Pharma today announced that it has appointed DrSøren Bregenholt as chief executive.

Dr Bregenholt is a Danish national with an extensive operational and strategic track record from the biotech and pharmaceutical industries. He previously held senior executive roles including chief operating officer and chief business officer at Danish biotech companies Symphogen and IO Biotech, respectively.

As part of the global R&D Management at Novo Nordisk (NOV: N), Dr Bregenholt was responsible for the global R&D Strategy and External Innovation efforts. Currently, Dr Bregenholt serves as chairman at the Danish-Swedish life science organization Medicon Valley Alliance. His academic career, at the University of Copenhagen and Institute Pasteur, Paris, has focussed on immunoregulation and immunopathology in cancer and other diseases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK